ArticleGlobal health action2024
Social vulnerability index associated with higher COVID-19 seroprevalence in Nigeria.
Article in Global health action, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Social vulnerability has been shown to be a strong predictor of disparities in health outcomes. A common approach to estimating social vulnerability is using a composite index, such as the social vulnerability index (SVI), which combines multiple factors corresponding to key social determinants of health. Lawal and Osayomi created an SVI to explore key social determinants of health-related COVID-19 infection among the Nigerian population. This study explored the association of COVID-19 SVI with COVID-19 seroprevalence using a large household survey in Nigeria. Weighted COVID-19 seroprevalence estimates at the Local Government Areas (LGA) were estimated and merged with the Lawal and Osayomi SVI, also at the LGA-level. Linear regression models were constructed to evaluate the relationship between the SVI and COVID-19 seroprevalence. The effect of SVI was evaluated both as a continuous variable and categorized into quintiles to evaluate dose-response effects. Our results confirmed a positive relationship between social vulnerability and COVID-19 infection in four states and the Federal Capital Territory in Nigeria. Compared to class 1 (the least vulnerable group), COVID-19 seroprevalence was, on average, 9.21% and 6.42% higher in classes 4 and 5 LGAs, respectively, after adjustment by phase of the survey. The effect was particularly strong farther into the pandemic (June 2021), when COVID-19 mitigation measures were relaxed. In conclusion, SVI can potentially be a useful tool to effectively prioritize communities for resource allocation as part of emergency response and preparedness in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.